Monte Rosa Therapeutics, Inc. Stock-Based Compensation
Monte Rosa Therapeutics, Inc. (GLUE) reported Stock-Based Compensation of $11.92 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ShareBasedCompensation · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-06-30 was $5.97M, a 21.99% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2026-03-31 was $5.95M, a 12.29% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-12-31 was $4.31M, a 3.58% decline year-over-year.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for the quarter ending 2025-09-30 was $4.36M, a 1.91% increase year-over-year.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2025 was $18.86M, a 4.08% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2024 was $18.13M, a 8.74% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2023 was $16.67M, a 42.91% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. share-based payment arrangement, noncash expense for fiscal 2022 was $11.66M, a 124.31% increase from fiscal 2021.
| Period end | Share-based Payment Arrangement, Noncash Expense 3 month | Share-based Payment Arrangement, Noncash Expense 6 month | Share-based Payment Arrangement, Noncash Expense 9 month | Share-based Payment Arrangement, Noncash Expense 12 month |
|---|---|---|---|---|
| 2026-06-30 | $5.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $11.92M 10-Q · filed 2026-08-06 | $16.23M derived: sum of 3 quarters · filed 2026-08-06 | $20.59M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $5.95M 10-Q · filed 2026-05-07 | $10.26M derived: sum of 2 quarters · filed 2026-05-07 | $14.62M derived: sum of 3 quarters · filed 2026-05-07 | $19.52M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $4.31M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.67M derived: sum of 2 quarters · filed 2026-03-17 | $13.57M derived: sum of 3 quarters · filed 2026-08-06 | $18.86M 10-K · filed 2026-03-17 |
| 2025-09-30 | $4.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $9.26M derived: sum of 2 quarters · filed 2026-08-06 | $14.56M 10-Q · filed 2025-11-06 | $19.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $4.89M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $10.19M 10-Q · filed 2026-08-06 | $14.66M derived: sum of 3 quarters · filed 2026-08-06 | $18.94M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $5.30M 10-Q · filed 2026-05-07 | $9.77M derived: sum of 2 quarters · filed 2026-05-07 | $14.05M derived: sum of 3 quarters · filed 2026-05-07 | $18.55M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $4.47M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $8.75M derived: sum of 2 quarters · filed 2026-03-17 | $13.25M derived: sum of 3 quarters · filed 2026-03-17 | $18.13M 10-K · filed 2026-03-17 |
| 2024-09-30 | $4.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $8.78M derived: sum of 2 quarters · filed 2025-11-06 | $13.66M 10-Q · filed 2025-11-06 | $17.73M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $4.50M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $9.38M 10-Q · filed 2025-08-07 | $13.45M derived: sum of 3 quarters · filed 2025-08-07 | $17.92M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $4.87M 10-Q · filed 2025-05-08 | $8.95M derived: sum of 2 quarters · filed 2025-05-08 | $13.41M derived: sum of 3 quarters · filed 2025-05-08 | $17.57M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $4.07M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $8.54M derived: sum of 2 quarters · filed 2025-03-20 | $12.70M derived: sum of 3 quarters · filed 2025-03-20 | $16.67M 10-K · filed 2025-03-20 |
| 2023-09-30 | $4.47M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $8.62M derived: sum of 2 quarters · filed 2024-11-07 | $12.60M 10-Q · filed 2024-11-07 | $15.92M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $4.15M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $8.13M 10-Q · filed 2024-08-08 | $11.45M derived: sum of 3 quarters · filed 2024-08-08 | $14.67M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | $3.97M 10-Q · filed 2024-05-09 | $7.30M derived: sum of 2 quarters · filed 2024-05-09 | $10.51M derived: sum of 3 quarters · filed 2024-05-09 | $13.39M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $3.33M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $6.54M derived: sum of 2 quarters · filed 2024-03-14 | $9.41M derived: sum of 3 quarters · filed 2024-03-14 | $11.66M 10-K · filed 2024-03-14 |
| 2022-09-30 | $3.21M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $6.09M derived: sum of 2 quarters · filed 2023-11-09 | $8.34M 10-Q · filed 2023-11-09 | $10.19M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $2.87M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | $5.12M 10-Q · filed 2023-08-10 | $6.98M derived: sum of 3 quarters · filed 2023-08-10 | $9.05M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $2.25M 10-Q · filed 2023-05-11 | $4.11M derived: sum of 2 quarters · filed 2023-05-11 | $6.18M derived: sum of 3 quarters · filed 2023-05-11 | $7.20M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | $1.86M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $3.93M derived: sum of 2 quarters · filed 2023-03-16 | $4.95M derived: sum of 3 quarters · filed 2023-03-16 | $5.20M 10-K · filed 2023-03-16 |
| 2021-09-30 | $2.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $3.09M derived: sum of 2 quarters · filed 2022-11-10 | $3.34M 10-Q · filed 2022-11-10 | $3.54M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $1.27M 10-Q · filed 2022-08-11 | $1.47M derived: sum of 3 quarters · filed 2022-08-11 | $1.52M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | $252.00K 10-Q · filed 2022-05-11 | $453.00K derived: sum of 2 quarters · filed 2022-05-11 | $498.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $201.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $246.00K derived: sum of 2 quarters · filed 2022-03-29 | $354.00K 10-K · filed 2022-03-29 | |
| 2020-09-30 | $45.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $153.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $108.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |